Clovis Oncology aims for its first New Drug Application (NDA) submission by 2015. Lined up is a global Phase 3 registration study for rucaparib and plans to initiate registration studies for CO-1686 in the second quarter of 2014 (Press release Clovis Oncology, FEB 27, 2014, View Source [SID:1234500190]).
Clovis Oncology Announces 2013 Operating Results and Expands CO-1686 Development Program
Clovis Oncology aims for its first New Drug Application (NDA) submission by 2015. Lined up is a global Phase 3 registration study for rucaparib and plans to initiate registration studies for CO-1686 in the second quarter of 2014 (Press release Clovis Oncology, FEB 27, 2014, View Source [SID:1234500190]).